Lyell Immunopharma opened lower at $16.70, compared with its previous close of $16.86. In the last trading session, the stock traded between $15.54 and $16.86. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Lyell Immunopharma is now worth
$ 6.77
Resulting in a loss of
$ 93.23 (93.23%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
80%
Hold
0%
Sell
20%
Markets Today
Today's Change
$-1.26 (-7.45%)
Day High
$16.86
Day Low
$15.54
Day Open
$16.70
Prev Close
$16.86
Volume
1,05,716
1W Return
1.09%
1M Return
88.68%
3M Return
4.76%
6M Return
-18.73%
1Y Return
-9.54%
Fundamentals
Market Cap ($ Mn)
384
PE Ratio
-
PB Ratio
1.45
PEG Ratio
-
ROE
-86.00%
ROCE
-78.10%
EPS (TTM)
$-1.85
Investment Returns
1 Week
1.09%
1 Month
88.68%
3 Months
4.76%
6 Months
-18.73%
9 Months
-35.89%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
3Nov
Needham reiterates Buy on Lyell Immunopharma with $44 target
Needham analyst Gil Blum reiterated a Buy rating on Lyell Immunopharma. The firm maintained its price target at $44 per share. No changes were made to the existing investment thesis or valuation.
9 days ago
22Jul
B. Riley initiates coverage on Lyell with Buy rating
B. Riley Securities analyst Yuan Zhi initiated coverage on Lyell Immunopharma with a Buy rating and a price target of $44, indicating a positive outlook for the stock.
3mo ago
15Jun
Citizens reiterates Market Outperform on Lyell Immunopharma
Citizens analyst Reni J. Benjamin has reiterated a Market Outperform rating for Lyell Immunopharma, maintaining a price target of $34. The rating reflects a positive outlook on the company's stock.
5mo ago
15Jun
Needham reiterates Buy on Lyell Immunopharma, maintains $44 target
Needham analyst Gil Blum has reiterated a Buy rating for Lyell Immunopharma (NASDAQ: LYEL) with a maintained price target of $44, signaling confidence in the stock's valuation potential.
5mo ago
12Jun
Lyell Immunopharma reports ronde-cel safety data at EHA 2026
Lyell Immunopharma presented updated safety and translational data for ronde-cel at EHA 2026, showing no Grade ≥ 3 CRS and a 97% manufacturing success rate. The trial included 108 patients with high-risk disease characteristics. Key milestones include updated data in H2 2026 and a BLA submission in H2 2027.
5mo ago
9Jun
HC Wainwright reiterates Buy on Lyell Immunopharma
HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a Buy rating on Lyell Immunopharma, maintaining a price target of $45.
